Literature DB >> 24403302

Impact of new antifungal breakpoints on antifungal resistance in Candida species.

Annette W Fothergill1, Deanna A Sutton, Dora I McCarthy, Nathan P Wiederhold.   

Abstract

We reviewed our antifungal susceptibility data for micafungin, anidulafungin, fluconazole, and voriconazole against Candida species and compared resistance rates determined by the previous and recently revised CLSI antifungal breakpoints. With the new breakpoints, resistance was significantly increased for micafungin (from 0.8% to 7.6%), anidulafungin (from 0.9% to 7.3%), and voriconazole (from 6.1% to 18.4%) against Candida glabrata. Resistance was also increased for fluconazole against Candida albicans (from 2.1% to 5.7%).

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24403302      PMCID： PMC3957792          DOI： 10.1128/JCM.03044-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  17 in total

1.  Breakthrough invasive candidiasis in patients on micafungin.

Authors:  Christopher D Pfeiffer; Guillermo Garcia-Effron; Aimee K Zaas; John R Perfect; David S Perlin; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

Review 2.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

3.  Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).

Authors:  Isabel Cuesta; Concha Bielza; Manuel Cuenca-Estrella; Pedro Larrañaga; Juan L Rodríguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2010-02-01       Impact factor: 5.191

4.  In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.

Authors:  Michael A Pfaller; Shawn A Messer; Paul R Rhomberg; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-06-05       Impact factor: 5.948

5.  Clinical significance of azole antifungal drug cross-resistance in Candida glabrata.

Authors:  Anil A Panackal; Jennifer L Gribskov; Janet F Staab; Katherine A Kirby; Michael Rinaldi; Kieren A Marr
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

6.  Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2006-11-01       Impact factor: 5.948

7.  Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

8.  Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-12-19       Impact factor: 5.948

9.  Association of fluconazole pharmacodynamics with mortality in patients with candidemia.

Authors:  John W Baddley; Mukesh Patel; Sujata M Bhavnani; Stephen A Moser; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

10.  Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.

Authors:  Juan L Rodríguez-Tudela; Benito Almirante; Dolors Rodríguez-Pardo; Fernando Laguna; J Peter Donnelly; Johan W Mouton; Albert Pahissa; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191
View more
  24 in total

1.  Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy.

Authors:  Sandra A Asner; Stefano Giulieri; Manuel Diezi; Oscar Marchetti; Dominique Sanglard
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

2.  Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis.

Authors:  Julie Autmizguine; Sylvia Tan; Michael Cohen-Wolkowiez; C Michael Cotten; Nathan Wiederhold; Ronald N Goldberg; Ira Adams-Chapman; Barbara J Stoll; P Brian Smith; Daniel K Benjamin
Journal:  Pediatr Infect Dis J       Date:  2018-09       Impact factor: 2.129

3.  Do we need to adopt antifungal stewardship programmes?

Authors:  Konstantinos Ioannidis; Apostolos Papachristos; Ioannis Skarlatinis; Fevronia Kiospe; Sotiria Sotiriou; Eleni Papadogeorgaki; George Plakias; Vangelis D Karalis; Sophia L Markantonis
Journal:  Eur J Hosp Pharm       Date:  2018-06-28

4.  Quantitative Microplate-Based Growth Assay for Determination of Antifungal Susceptibility of Histoplasma capsulatum Yeasts.

Authors:  Kristie D Goughenour; Joan-Miquel Balada-Llasat; Chad A Rappleye
Journal:  J Clin Microbiol       Date:  2015-08-05       Impact factor: 5.948

5.  Antifungal susceptibilities of bloodstream isolates of Candida species from nine hospitals in Korea: application of new antifungal breakpoints and relationship to antifungal usage.

Authors:  Eun Jeong Won; Jong Hee Shin; Min Ji Choi; Wee Gyo Lee; Yeon-Joon Park; Young Uh; Shine-Young Kim; Mi-Kyung Lee; Soo Hyun Kim; Myung Geun Shin; Soon Pal Suh; Dong Wook Ryang
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

6.  An automated high-throughput cell-based multiplexed flow cytometry assay to identify novel compounds to target Candida albicans virulence-related proteins.

Authors:  Stella M Bernardo; Christopher P Allen; Anna Waller; Susan M Young; Tudor Oprea; Larry A Sklar; Samuel A Lee
Journal:  PLoS One       Date:  2014-10-28       Impact factor: 3.240

7.  Drug-resistant Candida glabrata infection in cancer patients.

Authors:  Dimitrios Farmakiotis; Jeffrey J Tarrand; Dimitrios P Kontoyiannis
Journal:  Emerg Infect Dis       Date:  2014-11       Impact factor: 6.883

Review 8.  Emerging Threats in Antifungal-Resistant Fungal Pathogens.

Authors:  Dominique Sanglard
Journal:  Front Med (Lausanne)       Date:  2016-03-15

9.  Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.

Authors:  Hatice Turk Dagi; Duygu Findik; Cigdem Senkeles; Ugur Arslan
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-05-31       Impact factor: 3.944

10.  In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey.

Authors:  Gulgun Yenisehirli; Nermin Bulut; Aydan Yenisehirli; Yunus Bulut
Journal:  Jundishapur J Microbiol       Date:  2015-09-08       Impact factor: 0.747
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.